Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The Oxford Epilepsy Research Group is at the forefront of some potentially ground-breaking work with patients who have drug-resistant epilepsy. Epilepsy affects over 50 million people worldwide and nearly one in three people with epilepsy are resistant to current drugs.

In August 2018, LivaNova PLC launched a global registry to evaluate the use of its Vagus Nerve Stimulation Therapy® (VNS Therapy) System for patients with drug-resistant epilepsy.

The system consists of two implantable components: a programmable electronic pulse generator that is connected to a bipolar electrical lead, which sends mild pulses to stimulate the vagus nerve at regular intervals throughout the day.

This study will enroll up to 2,000 patients and follow them for five years. The analysis of the data from this large repository will help to evaluate the safety and effectiveness of this therapy, as well as clinical outcomes for patients.

The Oxford Epilepsy Research Group, led by Arjune Sen, enrolled the first patient in Europe to the trial, and has recruited the largest number of patients to the study so far, along with Child Neurology Consultants Austin, Dr Keough.

Child Neurology Consultants Austin, Dr. Keough​

 

Similar stories

New study shows clinical symptoms for Alzheimer’s can be predicted in preclinical models

Establishing preclinical models of Alzheimer’s that reflect in-life clinical symptoms of each individual is a critically important goal, yet so far it has not been fully realised. A new collaborative study from the University of Oxford has demonstrated that clinical vulnerability to an abnormally abundant protein in Alzheimer’s brain is in fact reflected in individual patient induced pluripotent stem cell-derived cortical neurons.

New insights gained into how the brain encodes information about the world

Scientists have developed a new way to test the theory that active neurons can change what they signal in the world, rather than keeping a stable correspondence to things (such as a features of an object, or ideas).

Oxford and Quinnipiac researchers discuss integrated clinical care, education, and research in multiple sclerosis

Mount Sinai Rehabilitation Hospital's Mandell Center for Multiple Sclerosis Care and Neuroscience Research welcomed University of Oxford partners in September. Stakeholders from University of Oxford and Quinnipiac University met to discuss ongoing research and future opportunities to develop a Mandell MS Center concept of care in the UK.

Repurposed drug could help patients with motor neuron disease

A drug typically used to treat enlarged prostates and high blood pressure has shown promise as a potential new therapy for motor neuron disease (MND), according to a new study.

Finding out more about Parkinson’s by monitoring symptoms at home

Professor Chrystalina Antoniades explains how the COVID pandemic accelerated an innovation in one research project into Parkinson's Disease.